cjc-1295 dac ipamorelin (NO DAC) + – Research Peptide CJC-1295 Ipamorelin Blend 10mg | A phase II
Description
A phase II randomized study of osimertinib with or without local consolidative therapy for metastatic EGFR mutant non-small cell lung cancer
Most research on the peptide has been conducted in animal models rather than human clinical trials
Linear regression of gene expression was conducted with n = 432 samples from human aorta, n = 241 from coronary artery, and n = 664 from tibial artery from the GTEx dataset
Noth RH, Walter RM Jr
To schedule a consultation and start your peptide therapy, please contact us online
